XTX Topco Ltd Takes Position in Stryker Co. (NYSE:SYK)

XTX Topco Ltd bought a new position in shares of Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,843 shares of the medical technology company's stock, valued at approximately $1,384,000.

Several other hedge funds and other institutional investors have also made changes to their positions in SYK. Vanguard Group Inc. increased its position in Stryker by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock worth $11,773,213,000 after purchasing an additional 252,188 shares during the last quarter. FMR LLC increased its position in shares of Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after purchasing an additional 727,850 shares during the last quarter. Geode Capital Management LLC raised its holdings in Stryker by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after buying an additional 168,436 shares during the period. Norges Bank purchased a new position in Stryker during the fourth quarter worth $1,710,744,000. Finally, Invesco Ltd. increased its position in Stryker by 15.3% during the fourth quarter. Invesco Ltd. now owns 2,007,105 shares of the medical technology company's stock valued at $722,658,000 after acquiring an additional 266,587 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Price Performance

Shares of Stryker stock traded down $0.21 during mid-day trading on Friday, reaching $346.46. 1,349,873 shares of the stock traded hands, compared to its average volume of 1,362,954. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average of $371.83 and a 200 day moving average of $373.11. The stock has a market capitalization of $132.24 billion, a PE ratio of 44.65, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the firm posted $3.46 earnings per share. On average, analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.97%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SYK. Stifel Nicolaus boosted their target price on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Barclays upped their target price on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Citigroup reaffirmed a "buy" rating and issued a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. BTIG Research set a $403.00 price target on Stryker and gave the company a "buy" rating in a research note on Monday. Finally, The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research note on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and an average price target of $423.53.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.